2009 Press Releases
May 24, 2010
SyntheMed Receives CE Mark Approval for REPEL-GYN™
October 1, 2009
SyntheMed Completes $1.0 Million Equity Placement
September 9, 2009
SyntheMed Receives Brazilian Regulatory Approval for REPEL-CV™
August 18, 2009
SyntheMed Receives Russian Regulatory Approval for REPEL-CV™
August 7, 2009
REPEL-CV™ Adhesion Barrier Receives Endorsement of Kids With Heart
July 30, 2009
SyntheMed Receives US Patent on Novel Polymer Technology
May 28, 2009
SyntheMed Receives Australian Regulatory Approval for REPEL-CV®
March 9, 2009
FDA Approves SyntheMed's REPEL-CV® Adhesion Barrier for use in Pediatric Cardiac Surgery
2008 Press Releases
November 19, 2008
SyntheMed Announces FDA Clearance of SinusShield™
October 2, 2008
SyntheMed Announces New Management Appointments
October 1, 2008
SyntheMed Completes $4.0 Million Equity Placement
September 18, 2008
SyntheMed to Present at the AdvaMed 2008 Medtech Conference
July 18, 2008
SyntheMed Appoints Corinne Mundin as Director, International Market Development
July 15, 2008
SyntheMed Receives Canadian Approval for REPEL-CV®
May 20, 2008
SyntheMed, Inc. Adopts Shareholder Rights Plan
February 26, 2008
SyntheMed to Present at Canaccord Adams’ Small-cap Orthopedics Conference
> Return to top.
2007 Press Releases
November 7, 2007
SyntheMed Files Universal Shelf Registration
November 2, 2007
SyntheMed to Present at the Acumen BioFin Conference
September 20, 2007
FDA Panel Recommends Approval of SyntheMed’s REPEL-CV® Adhesion Barrier for Pediatric Patients
September 12, 2007
SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
August 14, 2007
SyntheMed Completes $2.8 Million Equity Financing
June 21, 2007
SyntheMed’s Pre-market Approval (PMA) Application for REPEL-CV® to Be Reviewed by FDA Panel
May 2, 2007
SyntheMed Appoints Marc Sportsman as Vice President of Sales
March 28, 2007
FDA Accepts SyntheMed’s Pre-market Approval (PMA) Application for REPEL-CV®
> Return to top.